Agios Pharmaceuticals マネジメント
マネジメント 基準チェック /44
Agios Pharmaceuticalsの CEO はBrian Goffで、 Aug2022年に任命され、 の在任期間は 2.25年です。 の年間総報酬は$ 3.42Mで、 23.4%給与と76.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.14%を直接所有しており、その価値は$ 4.30M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と7.6年です。
主要情報
Brian Goff
最高経営責任者
US$3.4m
報酬総額
| CEO給与比率 | 23.4% |
| CEO在任期間 | 2.3yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 2.8yrs |
| 取締役会の平均在任期間 | 7.6yrs |
経営陣の近況
Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
報酬と市場: Brianの 総報酬 ($USD 3.42M ) は、 US市場 ($USD 6.60M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Brianの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Brian Goff (55 yo)
2.3yrs
在職期間
US$3,416,453
報酬
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.3m | |
| Chief Financial Officer | 2.2yrs | US$1.21m | 0.035% $ 1.1m | |
| Corporate Secretary & Chief Legal Officer | 2.8yrs | US$1.93m | 0.028% $ 857.6k | |
| Chief Medical Officer and Head of Research & Development | 3.2yrs | US$2.87m | 0.077% $ 2.4m | |
| Chief Commercial Officer | 1.8yrs | US$3.73m | 0.023% $ 723.0k | |
| Founder | no data | US$333.51k | データなし | |
| Founder | no data | データなし | データなし | |
| Founder | no data | データなし | データなし | |
| Founder | no data | データなし | データなし | |
| VP, Controller & Principal Accounting Officer | 3.3yrs | データなし | 0.0014% $ 44.5k | |
| Chief Technical Operations Officer | 7.4yrs | データなし | データなし | |
| Vice President of Investor Relations & Corporate Communications | no data | データなし | データなし |
2.8yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: AGIOの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.3m | |
| Chair of the Board of Directors | 6.9yrs | US$447.25k | 0.25% $ 7.7m | |
| Independent Director | 1.4yrs | US$663.68k | 0.0035% $ 107.8k | |
| Member of Scientific Advisory Board | 8.3yrs | US$302.85k | データなし | |
| Member of Scientific Advisory Board | 15.8yrs | データなし | データなし | |
| Lead Independent Director | 9.9yrs | US$440.95k | 0.013% $ 412.4k | |
| Independent Director | 15.3yrs | US$417.25k | 0.83% $ 26.0m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 16yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.8yrs | US$3.21m | データなし | |
| Independent Director | 2.3yrs | US$419.91k | 0.014% $ 436.4k | |
| Member of Scientific Advisory Board | no data | データなし | データなし |
7.6yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: AGIOの 取締役会 は 経験豊富 であると考えられます ( 7.6年の平均在任期間)。